Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: New Indication For Lucentis; New Lesinurad Application From Ironwood

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says
Agile's Phase III Data For Twirla Patch Fall Flat, Raise Doubts On Approval
Nonprofit Medicines360 Provides Affordable Contraception, Women’s Health
Harvoni Approval Led To Narrowing Of Epclusa's Breakthrough Status
Keeping Track: FDA Rejects Mealtime Insulin, Antihistamine; Misses Goal For Another Opioid
Ironwood Buys AstraZeneca's Zurampic As Ideal Linzess Complement
AstraZeneca’s Gout Drug Zurampic Clears FDA; Renal, CV Safety Trial Required

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel